What is CRBP (CRBP) stock price today?

CRBP (CRBP) is currently trading at $9.11, up 0.33% today.

What is CRBP P/E ratio?

CRBP's P/E ratio is -1.95. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CRBP return on equity (ROE)?

CRBP's return on equity (ROE) is -53.38%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CRBP's market cap?

CRBP has a market capitalization of $168.79M.

NASDAQ · Biotechnology

CRBP (CRBP) Stock

$9.11 +0.33% NASDAQ: CRBP Healthcare

Valuation

Metric	Value
Price	$9.11
Market Cap	$168.79M
P/E Ratio	-1.95
P/B Ratio	0.98
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$20.56
52-Week Low	$6.10
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-53.38%
ROA	-47.02%
ROCE	-57.82%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	7.95

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$0	$0	$0	$0
Operating Profit	$-56.0M	$-35.0M	$-45.0M	$-49.0M	$-85.0M
Net Profit	$-46.0M	$-56.0M	$-45.0M	$-40.0M	$-79.0M
EPS	$-11.13	$-10.15	$-10.31	$-3.68	$-5.90
Op Margin	-6350.1%	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$108.0M	$66.0M	$28.0M	$156.0M	$168.0M
Total Liabilities	$39.0M	$33.0M	$35.0M	$13.0M	$21.0M
Cash	$25.0M	$17.0M	$14.0M	$17.0M	$28.0M
Borrowings	$27.0M	$25.0M	$21.0M	$3.0M	$2.0M

Latest News

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer GlobeNewswire · Jul 6, 2026 Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating MT Newswires · Jun 17, 2026 Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near MarketBeat · Jun 9, 2026 Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study MarketBeat · Jun 1, 2026 Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-48.0M	$-38.0M	$-36.0M	$-42.0M	$-64.0M
Investing Cash Flow	$-73.0M	$30.0M	$36.0M	$-121.0M	$-2.0M
Financing Cash Flow	$-2.0M	$0	$0	$0	$0
Net Cash Flow	$-61.0M	$-8.0M	$-3.0M	$3.0M	$11.0M
Free Cash Flow	$-48.0M	$-38.0M	$-36.0M	$-42.0M	$-64.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-51.05%
Quick Ratio	7.92
Interest Coverage	—
Return 1Y	11.17%
Return 3Y	16.82%
Return 5Y	-79.82%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALEC	$1.52	+0.33%	-1.58	$168.20M	0.00%
APLTApplied Therapeutics, Inc.	$0.10	+0.00%	-0.24	$14.86M	0.00%
CRDF	$0.81	-2.98%	-2.58	$53.22M	0.00%
ELTXElicio Therapeutics, Inc.	$3.01	+0.17%	-1.27	$57.29M	0.00%
FBRX	$76.57	+0.08%	-4.26	$1.57B	0.00%

About CRBP

CRBP is led by CEO Yuval Cohen, employs 28 people, headquartered in US, publicly traded since 2014.

CRBP stock trades at $9.11 with a market capitalization of $168.79M. The stock is valued at a price-to-earnings (P/E) ratio of -1.95, price-to-book of 0.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $6.10 and $20.56, and currently trades 55.7% below its 52-week high.

On profitability, CRBP generates a return on equity (ROE) of -53.38%, return on capital employed of -57.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides